Evidence map›Paper›PMID 42426151›Full record

ArticleEuropean journal of human genetics : EJHG2026

Integrative and systematic genomic approaches to improve diagnosis in rare and undiagnosed diseases: results from the RareBoost project.

Ayca Yigit, Mert Pekerbas, Baris Salman, Kutay Bulut, Emre Ozzeybek, Mehmet Mert Topaloglu, Burcu Akman, Ravza Nur Yildirim, Sinem Aktug, Tugce Batur and 2 more

Abstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Genomics cycle: discover, diagnose, interpret, act.European journal of human genetics : EJHG · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ayca YigitRare and Undiagnosed Diseases Group, Izmir Biomedicine and Genome Center, Izmir, Türkiye.
Mert PekerbasRare and Undiagnosed Diseases Group, Izmir Biomedicine and Genome Center, Izmir, Türkiye.
Baris SalmanRare and Undiagnosed Diseases Group, Izmir Biomedicine and Genome Center, Izmir, Türkiye.
Kutay BulutRare and Undiagnosed Diseases Group, Izmir Biomedicine and Genome Center, Izmir, Türkiye.ORCID http://orcid.org/0009-0007-4853-7519
Emre OzzeybekRare and Undiagnosed Diseases Group, Izmir Biomedicine and Genome Center, Izmir, Türkiye.
Mehmet Mert TopalogluRare and Undiagnosed Diseases Group, Izmir Biomedicine and Genome Center, Izmir, Türkiye.ORCID http://orcid.org/0000-0003-4892-7406
Burcu AkmanRare and Undiagnosed Diseases Group, Izmir Biomedicine and Genome Center, Izmir, Türkiye.
Ravza Nur YildirimRare and Undiagnosed Diseases Group, Izmir Biomedicine and Genome Center, Izmir, Türkiye.
Sinem AktugRare and Undiagnosed Diseases Group, Izmir Biomedicine and Genome Center, Izmir, Türkiye.
Tugce BaturRare and Undiagnosed Diseases Group, Izmir Biomedicine and Genome Center, Izmir, Türkiye.
Rare and Undiagnosed Diseases Advisory Board Consortium
Ugur OzbekRare and Undiagnosed Diseases Group, Izmir Biomedicine and Genome Center, Izmir, Türkiye. ugur.ozbek@ibg.edu.tr.ORCID http://orcid.org/0000-0001-5319-0547

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rare and undiagnosed diseases pose diagnostic challenges due to phenotypic and genetic heterogeneity and the limitations of conventional molecular testing. As part of the RareBoost project, we implemented an integrated, stepwise genomic strategy in a cohort of 134 patients from 120 families with previously inconclusive genetic testing. Our strategy combined systematic exome sequencing with subsequent genome sequencing when indicated, followed by targeted RNA-sequencing, and complemented with comprehensive phenotyping and follow-up segregation analysis. Definitive molecular diagnoses (pathogenic/likely pathogenic variants) were achieved in 25.0% of families, and an additional 25.8% harbored clinically relevant variants of uncertain significance with phenotypic correlation. This approach identified non-coding and structural variants while resolving cases through systematic reanalysis of previously negative data. Collectively, our findings demonstrate that integrated genomic and transcriptomic analyses with reanalysis of existing data enhance diagnostic yield in complex rare disease cohorts and provide a scalable framework for implementing genomic medicine in clinical practice.

Indexed as

Genetic TestingGenomicsRare DiseasesUndiagnosed DiseasesExome SequencingHumans

Identifiers

PMID42426151
PMCPMC13634047

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.